- ￥1699
- Sino Biological
- 13133-MM05
- 2025年08月12日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
100 µL
抗体种属：Human
抗体靶点：F3
抗体应用：ELISA,FCM,ICC/IF
抗原货号：13133-H08H
抗原描述：Recombinant Human F3 / Tissue factor / CD142 protein (Catalog#13133-H08H)
抗体宿主：Mouse
抗体Ig类型：Mouse IgG2a
抗体纯化方法：Protein A
抗体制备：This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human F3 / Tissue factor / CD142 (rh F3 / Tissue factor / CD142; Catalog#13133-H08H; P13726; Met 1-Glu 251). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
抗体特异性：Human F3 / Tissue factor / CD142
抗体保存：This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Identification of Mutations in the Human Factor VII Gene
It has been recognized from the early 1800s that activation of coagulation can be initiated by the exposure of subendothelial layers (tissue factor), but it was the 1940s before factor VII (FVII) was included in this event
Gene Therapy of X-Linked Severe Combined Immunodeficiency
to transduce ex vivo the CD34+cells of patients. This gene therapy protocol is currently being applied and the encouraging preliminary results published (1 ). The success of this protocol could be mainly attributed to the physiopathology of the SCID-X1 disease
Studies on Coagulation Incompatibilities for Xenotransplantation
) circulating PC in the presence of thrombin. Tissue factor pathway inhibitor (TFPI), is the primary inhibitor of tissue factor (TF)-induced coagulation. TFPI directly inhibits the activated factor X (FXa) and blocks the procoagulant activity of the TF/factor
技术资料暂无技术资料 索取技术资料
